ecancermedicalscience

Review

Brachytherapy reirradiation for local recurrences of gynaecological cancers: two clinical cases, literature review and OAR constraints

12 Mar 2026
Javier Faundez, Carlos Schananier, Cynthia Villegas, Javier Retamales

Background: Local recurrence of gynaecological malignancies after prior pelvic radiotherapy presents a complex therapeutic dilemma. Pelvic exenteration is curative in select cases but carries high morbidity and profound quality-of-life impact. Salvage reirradiation with image-guided brachytherapy (BT) offers a highly conformal alternative; however, data remain fragmented and practical organ-at-risk (OAR) constraints are not standardised.

Objectives: 1) To describe in detail two contemporary cases of high-dose-rate (HDR) BT reirradiation – one vulvar and one vaginal vault recurrence – highlighting planning strategy, catheter implantation, dosimetry and clinical outcome; 2) to synthesise current evidence on efficacy, toxicity, dose–fractionation and technique of BT reirradiation in cervical, endometrial and vulvar cancers; and 3) to propose pragmatic cumulative EQD2 OAR limits for rectum, bladder, small bowel and urethra based on published series.

Methods: Both patients underwent computed tomography/magnetic resonance imaging-based contouring with hybrid interstitial or surface mould applicators. Total doses were 45.6 Gy in 8 fractions (EQD210 ≈ 60 Gy) for the vulvar recurrence and 24.6 Gy in 3 fractions (EQD24.5 ≈ 48 Gy) for the vaginal vault recurrence, with cumulative OAR doses referenced against literature-derived thresholds. A narrative review (1993–2024) identified 35 key studies involving >600 reirradiated patients.

Results: The vulvar case achieved complete response at 6 months without Grade ≥3 toxicity; the vaginal vault case showed initial partial response, remained ECOG 0 and required systemic therapy for later progression. Across the literature, 1- to 3-year local control ranged 40%–80% and overall survival 40%–60%, with severe late toxicity generally ≤30% when cumulative doses respected D2cc ≈ 70–100 Gy3 (rectum), 90–120 Gy3 (bladder) and D0.5cc ≤ 110 Gy3(urethra). Fractionation of 4–6 Gy BID for 5–10 fractions (EQD210 ≈ 40–50 Gy) was most common.

Conclusion: HDR BT reirradiation can achieve meaningful, sometimes durable, local control in carefully selected gynaecologic-cancer recurrences while preserving pelvic organs. Adhering to proposed cumulative EQD2 OAR constraints and employing image-guided interstitial techniques are paramount to curtail severe complications. Multidisciplinary assessment and treatment at experienced centres are strongly recommended to optimise outcomes.

Artículos relacionados

G Luis Pendola, Roberto Elizalde, Pablo Sitic Vargas, José Caicedo Mallarino, Eduardo Gonzalez, José Parada, Mauricio Camus, Ricardo Schwartz, Enrique Bargalló, Ruffo Freitas, Mauricio Magalhaes Costa, Vilmar Marques de Oliveira, Paula Escobar, Miguel Oller, Luis Fernando Viaña, Antonio Jurado Bambino, Gustavo Sarria, Francisco Terrier, Roger Corrales, Valeria Sanabria, Juan Carlos Rodríguez Agostini, Gonzalo Vargas Chacón, Víctor Manuel Pérez, Verónica Avilés, José Galarreta, Guillermo Laviña, Jorge Pérez Fuentes, Lía Bueso de Castellanos, Bolívar Arboleda Osorio, Herbert Castillo, Claudia Figueroa
José Fernando Robles Díaz, Adela Heredia Zelaya, Alicia Milagros Avalos Rosas
María Eugenia Giavedoni, Lucas Staringer, Rosa Garrido, Cintia Bertoncini, Mabel Sardi, Myriam Perrotta
Sebastián Mondaca, Valentina Hornig, Pablo Munoz-Schuffenegger, Francisco Acevedo, Marcelo Garrido, Bruno Nervi